ICM Pharma invests €5.25 million in Alloksys Life Sciences to support Phase 3 clinical study trials of RESCAP® drug
ICM Pharma invests €5.25 million in Alloksys Life Sciences to support Phase 3 clinical study trials of RESCAP® drug This is the largest investment by a Singapore pharmaceutical manufacturer for clinical trial development ICM Pharma will have exclusive manufacturing and marketing rights for RESCAP® used in cardiothoracic surgery for the Asia Pacific Phase 3 clinical trials to be conducted in Singapore and other countries with National University Heart Centre, Singapore (NUHCS) to take lead in multi-centre trial Utrecht/Singapore, 31 May 2016 – Dutch based Alloksys Life Sciences BV has signed and closed agreements with the fastest growing local pharmaceutical company […]
Read more »